Drugs / E2511
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05147337 | Dec 2021 → Aug 2022 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04547361 | Sep 2020 → May 2021 | — | Eisai Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-07-21 | Eisai Inc. | Results EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEASE AND DEMENTIA AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2021 eisai.com ↗
A poster presentation will also be given on the results of an in vivo study of E2511, Eisai’s in-house discovered and developed investigational novel oral synapse regenerant. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04547361 ↗ |
| Route | Oral | “single ascending oral doses” NCT04547361 ↗ |